New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
09:19 EDTFOLD, COO, TSPT, AGEN, APP, NFLX, GEVA, GNRCOn The Fly: Pre-market Movers
HIGHER: Netflix (NFLX), up 3.6% after the stock was upgraded to Buy from Neutral at Goldman... Transcept Pharmaceuticals (TSPT), up 22.6% after signing a merger agreement with Paratek Pharmaceuticals... Agenus (AGEN), up 21% after announcing that in a Phase 2 study patients with newly diagnosed glioblastoma multiforme who received Agenusí Prophage autologous cancer vaccine added to the standard of care treatment lived nearly twice as long as expected... Galena Biopharma (GALE), up 11% after announcing the notice of allowance of a U.S. patent for NeuVax... Amicus Therapeutics (FOLD), up 11.7% following upgrades at Leerink and Janney Capital... Cooper Companies (COO), up 2.6% after agreeing to acquire Saulfon Pharmaceuticals, a European maker of soft contact lenses and solutions, in a transaction valued at approximately $1.2B. LOWER: American Apparel (APP), down 4% after former CEO Dov Charney disclosed he bought 27.35M shares on June 27... Generac (GNRC), down 3% following a downgraded to Neutral from Buy at BofA Merrill Lynch... Synageva (GEVA), down 2.7% after being initiated with a Neutral rating at Citigroup.
News For NFLX;TSPT;GNRC;APP;COO;GEVA;AGEN;FOLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 16, 2014
16:13 EDTAPPAmerican Apparel terminates Charney for cause, names Schneider as CEO
The board of directors of American Apparel announced that it has appointed Paula Schneider as CEO, effective January 5. This appointment follows the termination of Dov Charney, former President and CEO, for cause in accordance with the terms of his employment agreement. Scott Brubaker, who has been serving as Interim CEO, will continue in the post until Schneider joins the company, after which he will remain as a consultant to ensure an orderly transition. Charney was suspended as president and CEO by the Board on June 18 for alleged misconduct and violations of company policy. Under terms of an agreement signed by Charney on July 9, a special committee of the board oversaw an internal investigation conducted by FTI Consulting into the allegations against Charney. Based on this investigation, the special committee determined that it would not be appropriate for Charney to be reinstated as CEO or an officer or employee of the company. While under suspension as CEO, Charney had been serving as a consultant to the Company. This relationship has now been terminated.
16:12 EDTAPPAmerican Apparel terminates Dov Charney for cause
Subscribe for More Information
16:00 EDTNFLXOptions Update; December 16, 2014
iPath S&P 500 VIX Short-Term Futures up 1.55 to 34.60. Option volume leaders: AAPL TSLA TWTR AMZN FB C GILD BAC NFLX AA MGM MCD according to Track Data.
09:36 EDTNFLXActive equity options trading
Active equity options trading according to Track Data: AAPL AMZN C TSLA PBR TWTR NFLX JPM CLF ABX
09:17 EDTNFLXInternet sector upgraded to Attractive from Neutral at Goldman
Goldman upgraded the Americas Internet sector to Attractive to Neutral based on more reasonable valuations, reduced expectations, and strong sector growth. As part of the sector change, the firm upgraded GrubHub (GRUB) to Buy from Neutral, downgraded Shutterfly (SFLY) to Neutral from Buy, and lowered Priceline (PCLN) to Buy from Conviction Buy.
December 15, 2014
16:11 EDTCOOCooper Companies initiated with a Perform at Oppenheimer
Subscribe for More Information
16:00 EDTNFLXOptions Update; December 15, 2014
Subscribe for More Information
07:10 EDTGEVASynageva announces active IND for SBC-103
Synageva BioPharma announced that the investigational new drug, or IND, application to the FDA to evaluate SBC-103 as a treatment for mucopolysaccharidosis IIIB, also known as Sanfilippo B syndrome, is active. The company plans to start enrolling patients with MPS IIIB in a Phase 1/2 study investigating intravenous administration of SBC-103 shortly and to report preliminary data from this study in 2015. The company recently completed a study assessing the integrity of the blood-brain barrier and other disease abnormalities in patients with MPS IIIB and plans to report data during the first quarter of 2015. The company is also conducting natural history studies in MPS IIIB. These include a retrospective natural history study of deceased MPS IIIB patients that began in July 2013 and a prospective, longitudinal natural history study in living MPS IIIB patients that began in September 2014.
December 12, 2014
12:22 EDTNFLXNetflix introduces Atlas telemetry platform
Subscribe for More Information
06:33 EDTNFLXNetflix responds to FCC Commissioner's fast lanes allegations, TechCrunch says
Subscribe for More Information
December 11, 2014
16:01 EDTNFLXOptions Update; December 11, 2014
Subscribe for More Information
09:37 EDTNFLXActive equity options trading
Subscribe for More Information
07:32 EDTFOLDAmicus Therapeutics to submit EU MAA for migalastat HCl
Subscribe for More Information
December 9, 2014
16:00 EDTNFLXOptions Update; December 9, 2014
Subscribe for More Information
11:48 EDTNFLXStocks with call strike movement; NFLX TSLA
Subscribe for More Information
11:29 EDTNFLXDiscovery CEO says international market 'steady, good' for company
Subscribe for More Information
10:32 EDTNFLXNetflix hits a fresh 6-month low, levels to watch
Subscribe for More Information
06:48 EDTNFLXNetflix wants to be 'completely global' within five years, GigaOM reports
Netflix Chief Content Officer Ted Sarandos told investors at the UBS Global Media and Communications Conference that the company wants to be "completely global" and available everywhere in the world before 2020, GigaOM reports. CEO Reed Hastings has previously said that the company could eventually generate up to 80% of its revenue outside the U.S. Reference Link
December 8, 2014
11:29 EDTNFLXNetflix falls to session lows, levels to watch
The shares are down over 2% to $342.44. At that price next support is at $340.05. Resistance is at $345.45.
10:00 EDTNFLXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use